Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...

Disability progression in relapsing MS tends to follow one of four distinct patterns, according to a new study.

The FDA has rejected Sanofi's application seeking approval of tolebrutinib to treat certain forms of MS in its present form.

By analysing MRI scans and a simple blood test from hundreds of patients, researchers identified patterns that reveal how ...

Lipoic acid offers no improvements in walking speed or other outcomes in patients with progressive multiple sclerosis ...

Multiple sclerosis (MS) is a chronic autoimmune disease characterized by the disruption of nerve signals and various ...

For the first time, researchers have identified that inflammation—long associated with multiple sclerosis (MS)—appears to cause increased mutations linked to MS progression. MS is a progressive ...

Disability progression independent of relapse activity (PIRA) -- sometimes referred to as silent progression -- is a key integrating concept in the contemporary view of multiple sclerosis (MS). "The ...

New research reveals that when gut bacteria closely resemble the myelin sheath that protects nerve fibers, the immune system can become confused and attack both — accelerating multiple sclerosis.

The progression of relapsing-onset multiple sclerosis (MS) and its associated disability may be slowing, results from a large population-based study suggest. In an evaluation of more than 7000 ...

Two new sub-types of multiple sclerosis (MS) were discovered by researchers from Queen Square Analytics and University ...

Increasing evidence suggests that the severe gum disease, periodontitis, may contribute to central nervous system disorders ...